Treeline Biosciences CSO Jeffrey Engelman (L) and CEO Josh Bilenker
October 17, 2024 03:11 PM EDT
Financing
Startups

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Josh Bilenker and Jeff En­gel­man’s se­cre­tive start­up Tree­line Bio­sciences has an­oth­er $421 mil­lion, ac­cord­ing to a new SEC

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times